US Backs COVID Vaccines Patent Waiver, What Next for Jab Equality? episode artwork

EPISODE · May 6, 2021 · 21 MIN

US Backs COVID Vaccines Patent Waiver, What Next for Jab Equality?

from The Big Story · host The Quint

Extraordinary times call for extraordinary measures, and the US government backing a waiver on COVID-19 vaccine patents is just one of those crucial decisions that was much needed in this pandemic. As it is, low- and middle-income (LMIC) countries, like India, are facing a vaccine shortage without having vaccinated even 10 percent of the population, which makes it so utterly important to ramp up vaccine production across the world. The proposal was first floated by a group of LMICs, led by India and South Africa, at the World Trade Organisation in October 2020. They argued that such a move could speed up vaccine production, which in turn could accelerate inoculation drives. In this, they had the support of several advocacy groups, and even the WHO as well that believe that a pandemic is not the time for vaccine monopolies and profits. Although the US and other wealthy countries had strongly opposed the move for long to protect intellectual property rights, looking at gravity of the pandemic, the Biden administration has now decided to support a temporary waiver. But hold on! While that's certainly a good start, there's still a long way to go before we can actually see results of this decision. The US giving the green signal is a big move, but now it will have to negotiate at the WTO and secure a consensus from all 164 members, including the UK, the EU countries, Canada, Japan, Brazil, and all others that had blocked the waiver. So what kind of roadblocks are expected on the way? If the US does manage to clear the path, what happens next? What would a patent waiver entail for COVID vaccine manufacturers and why are pharma companies opposed to the move? And most importantly, what can a complete waiver mean for India? Tune in! Host and Producer: Shorbori Purkayastha Guest: Leena Menghaney, a lawyer who has worked extensively on public health and works with Access Campaign at Médecins Sans Frontières (MSF) Achal Prabhala, Coordinator of the Access IBSA project Amitabh Behar, Chief Executive Officer of Oxfam India Editor: Shelly Walia Music: Big Bang Fuzz Listen to The Big Story podcast on: Apple: https://apple.co/2AYdLIl Saavn: http://bit.ly/2oix78C Google Podcasts: http://bit.ly/2ntMV7S Spotify: https://spoti.fi/2IyLAUQ Deezer: http://bit.ly/2Vrf5Ng Castbox: http://bit.ly/2VqZ9ur Learn more about your ad choices. Visit megaphone.fm/adchoices

Extraordinary times call for extraordinary measures, and the US government backing a waiver on COVID-19 vaccine patents is just one of those crucial decisions that was much needed in this pandemic. As it is, low- and middle-income (LMIC) countries, like India, are facing a vaccine shortage without having vaccinated even 10 percent of the population, which makes it so utterly important to ramp up vaccine production across the world. The proposal was first floated by a group of LMICs, led by India and South Africa, at the World Trade Organisation in October 2020. They argued that such a move could speed up vaccine production, which in turn could accelerate inoculation drives. In this, they had the support of several advocacy groups, and even the WHO as well that believe that a pandemic is not the time for vaccine monopolies and profits. Although the US and other wealthy countries had strongly opposed the move for long to protect intellectual property rights, looking at gravity of the pandemic, the Biden administration has now decided to support a temporary waiver. But hold on! While that's certainly a good start, there's still a long way to go before we can actually see results of this decision. The US giving the green signal is a big move, but now it will have to negotiate at the WTO and secure a consensus from all 164 members, including the UK, the EU countries, Canada, Japan, Brazil, and all others that had blocked the waiver. So what kind of roadblocks are expected on the way? If the US does manage to clear the path, what happens next? What would a patent waiver entail for COVID vaccine manufacturers and why are pharma companies opposed to the move? And most importantly, what can a complete waiver mean for India? Tune in! Host and Producer: Shorbori Purkayastha Guest: Leena Menghaney, a lawyer who has worked extensively on public health and works with Access Campaign at Médecins Sans Frontières (MSF) Achal Prabhala, Coordinator of the Access IBSA project Amitabh Behar, Chief Executive Officer of Oxfam India Editor: Shelly Walia Music: Big Bang Fuzz Listen to The Big Story podcast on: Apple: https://apple.co/2AYdLIl Saavn: http://bit.ly/2oix78C Google Podcasts: http://bit.ly/2ntMV7S Spotify: https://spoti.fi/2IyLAUQ Deezer: http://bit.ly/2Vrf5Ng Castbox: http://bit.ly/2VqZ9ur Learn more about your ad choices. Visit megaphone.fm/adchoices

NOW PLAYING

US Backs COVID Vaccines Patent Waiver, What Next for Jab Equality?

0:00 21:40

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Frequently Asked Questions

How long is this episode of The Big Story?

This episode is 21 minutes long.

When was this The Big Story episode published?

This episode was published on May 6, 2021.

What is this episode about?

Extraordinary times call for extraordinary measures, and the US government backing a waiver on COVID-19 vaccine patents is just one of those crucial decisions that was much needed in this pandemic. As it is, low- and middle-income (LMIC)...

Can I download this The Big Story episode?

Yes, you can download this episode by clicking the download button on the episode player, or subscribe to the podcast in your preferred podcast app for automatic downloads.
URL copied to clipboard!